Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs

Journal of Immunology

Volumn 187, Issue 4, 2011, Pages 1986-1997

  Thakker, Paresh ^a   Marusic, Suzana ^a,c   Stedman, Nancy L ^a   Lee, Katherine L ^a   McKew, John C ^a   Wood, Andrew ^a   Goldman, Samuel J ^a   Leach, Michael W ^a   Collins, Mary ^a   Kuchroo, Vijay K ^b   Wolf, Stanley F ^a   Clark, James D ^a   Hassan Zahraee, Mina ^a  

^a PFIZER INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Hooke Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; CYTOSOLIC PHOSPHOLIPASE A2; CYTOSOLIC PHOSPHOLIPASE A2ALPHA; ENZYME INHIBITOR; LIPOXYGENASE; NAPROXEN; UNCLASSIFIED DRUG; WAY 196025; ZILEUTON; ARACHIDONATE 5 LIPOXYGENASE; AUTACOID; MEMBRANE PROTEIN; PHOSPHOLIPASE A2 GROUP IV; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EFFECTOR CELL; FEMALE; LYMPHOCYTE PROLIFERATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; SWISS JAMES LAMBERT MOUSE; TISSUE INJURY; ANIMAL; ANTIGEN PRESENTING CELL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; ARACHIDONATE 5-LIPOXYGENASE; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; FEMALE; GROUP IV PHOSPHOLIPASES A2; HUMANS; INFLAMMATION MEDIATORS; MEMBRANE PROTEINS; MICE; MICROGLIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; T-LYMPHOCYTES;

EID: 80051949664     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002789     Document Type: Article

References (64)

1. Zamvil, S. S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8: 579-621. (Pubitemid 20135640)
2. Martin, R., and H. F. McFarland. 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32: 121-182.
3. Steinman, L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24: 511-514.
4. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971. (Pubitemid 44289062)
5. Steinman, L., and S. S. Zamvil. 2005. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26: 565-571. (Pubitemid 41726443)
6. Sriram, S., and I. Steiner. 2005. Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann. Neurol. 58: 939-945. (Pubitemid 41746884)
7. Steinman, L., and S. S. Zamvil. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60: 12-21.
8. Maron, R., W. W. Hancock, A. Slavin, M. Hattori, V. Kuchroo, and H. L. Weiner. 1999. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and antiinflammatory cytokines. Int. Immunol. 11: 1573-1580. (Pubitemid 29425748)
9. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181: 381-386.
10. Constantinescu, C. S., M. Wysocka, B. Hilliard, E. S. Ventura, E. Lavi, G. Trinchieri, and A. Rostami. 1998. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol. 161: 5097-5104. (Pubitemid 28492093)
11. Ichikawa, M., C. S. Koh, A. Inoue, J. Tsuyusaki, M. Yamazaki, Y. Inaba, Y. Sekiguchi, M. Itoh, H. Yagita, and A. Komiyama. 2000. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing - remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J. Neuroimmunol. 102: 56-66.
12. 't Hart, B. A., H. P. Brok, E. Remarque, J. Benson, G. Treacy, S. Amor, R. Q. Hintzen, J. D. Laman, J. Bauer, and E. L. Blezer. 2005. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a humananti- human IL-12p40 antibody. J. Immunol. 175: 4761-4768. (Pubitemid 41362018)
13. Brok, H. P., M. Van Meurs, E. Blezer, A. Schantz, D. Peritt, G. Treacy, J. D. Laman, J. Bauer, and B. A. 't Hart. 2002. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol. 169: 6554-6563. (Pubitemid 36903508)
14. Segal, B. M., C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, L. H. Kasper; Ustekinumab MS Investigators. 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebocontrolled, randomised, dose-ranging study. Lancet Neurol. 7: 796-804.
15. Longbrake, E. E., and M. K. Racke. 2009. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev. Neurother. 9: 319-321.
16. Vollmer, T. L., D. R. Wynn, M. S. Alam, and J. Valdes. 2011. A phase 2, 24- week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult. Scler. 17: 181-191.
17. Thakker, P., M. W. Leach, W. Kuang, S. E. Benoit, J. P. Leonard, and S. Marusic. 2007. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 178: 2589-2598. (Pubitemid 46233462)
18. Dore-Duffy, P., S. Y. Ho, and C. Donovan. 1991. Cerebrospinal fluid eicosanoid levels: Endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 41: 322-324.
19. Dore-Duffy, P., and C. Donovan. 1991. Functional desensitization of monocytes from patients with multiple sclerosis due to prostaglandin E. Clin. Immunol. Immunopathol. 61: 119-128.
20. Neu, I. S., G. Metzger, J. Zschocke, R. Zelezny, and E. Mayatepek. 2002. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol. Scand. 105: 63-66. (Pubitemid 34188273)
21. Callea, L., M. Arese, A. Orlandini, C. Bargnani, A. Priori, and F. Bussolino. 1999. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 94: 212-221. (Pubitemid 29071262)
22. Kudo, I., and M. Murakami. 2002. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 68-69: 3-58.
23. Funk, C. D. 2001. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294: 1871-1875. (Pubitemid 33101574)
24. Marusic, S., M. W. Leach, J. W. Pelker, M. L. Azoitei, N. Uozumi, J. Cui, M. W. H. Shen, C. M. DeClercq, J. S. Miyashiro, B. A. Carito, et al. 2005. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 202: 841-851. (Pubitemid 41345972)
25. Kihara, Y., S. Ishii, Y. Kita, A. Toda, A. Shimada, and T. Shimizu. 2005. Dual phase regulation of experimental allergic encephalomyelitis by plateletactivating factor. J. Exp. Med. 202: 853-863. (Pubitemid 41345973)
26. Gladue, R. P., L. A. Carroll, A. J. Milici, D. N. Scampoli, H. A. Stukenbrok, E. R. Pettipher, E. D. Salter, L. Contillo, and H. J. Showell. 1996. Inhibition of leukotriene B4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J. Exp. Med. 183: 1893-1898. (Pubitemid 26134329)
27. Muthian, G., H. P. Raikwar, C. Johnson, J. Rajasingh, A. Kalgutkar, L. J. Marnett, and J. J. Bright. 2006. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J. Clin. Immunol. 26: 73-85. (Pubitemid 43112627)
28. Ni, J., Y. Y. Shu, Y. N. Zhu, Y. F. Fu,W. Tang, X. G. Zhong, H.Wang, Y. F. Yang, J. Ren, M. W. Wang, and J. P. Zuo. 2007. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL- 10 production by inhibiting T-bet expression. J. Neuroimmunol. 186: 94-103. (Pubitemid 46770867)
29. Lee, K. L., M. A. Foley, L. Chen, M. L. Behnke, F. E. Lovering, S. J. Kirincich, W. Wang, J. Shim, S. Tam, M. W. Shen, et al. 2007. Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J. Med. Chem. 50: 1380-1400. (Pubitemid 46504977)
30. McKew, J. C., K. L. Lee, M. W. Shen, P. Thakker, M. A. Foley, M. L. Behnke, B. Hu, F. W. Sum, S. Tam, Y. Hu, et al. 2008. Indole cytosolic phospholipase A2 alpha inhibitors: Discovery and in vitro and in vivo characterization of 4-3-[5- chloro-2-(2-[(3,4-dichlorobenzyl)sulfonyl] aminoethyl)-1-(diphenylmethyl)-1Hindol- 3-yl]propylbenzoic acid, efipladib. J. Med. Chem. 51: 3388-3413. (Pubitemid 351874997)
31. Ramarao, M. K., M. W. Shen, E. A. Murphy, W. Duan, Y. Zhao, J. McKew, K. L. Lee, P. Thakker, M. L. Behnke, and J. D. Clark. 2008. Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. Anal. Biochem. 383: 217-225.
32. Marusic, S., P. Thakker, J. W. Pelker, N. L. Stedman, K. L. Lee, J. C. McKew, L. Han, X. Xu, S. F. Wolf, A. J. Borey, et al. 2008. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 204: 29-37.
33. Napolitani, G., E. V. Acosta-Rodriguez, A. Lanzavecchia, and F. Sallusto. 2009. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFNgamma production by memory CD4+ T cells. Eur. J. Immunol. 39: 1301-1312.
34. Boniface, K., K. S. Bak-Jensen, Y. Li, W. M. Blumenschein, M. J. McGeachy, T. K. McClanahan, B. S. McKenzie, R. A. Kastelein, D. J. Cua, and R. De Waal Malefyt. 2009. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206: 535-548.
35. McMahon, B., and C. Godson. 2004. Lipoxins: Endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 286: F189-F201. (Pubitemid 38141663)
36. Serhan, C. N. 2005. Novel omega - 3-derived local mediators in antiinflammation and resolution. Pharmacol. Ther. 105: 7-21.
37. Huang, J. T., J. S. Welch, M. Ricote, C. J. Binder, T. M. Willson, C. Kelly, J. L. Witztum, C. D. Funk, D. Conrad, and C. K. Glass. 1999. Interleukin-4- dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400: 378-382. (Pubitemid 29344205)
38. Niino, M., K. Iwabuchi, S. Kikuchi, M. Ato, T. Morohashi, A. Ogata, K. Tashiro, and K. Onoé. 2001. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor- gamma. J. Neuroimmunol. 116: 40-48. (Pubitemid 32322638)
39. Marusic, S., J. S. Miyashiro, J. Douhan, III, R. F. Konz, D. Xuan, J. W. Pelker, V. Ling, J. P. Leonard, and K. A. Jacobs. 2002. Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neurosci. Lett. 332: 185-189. (Pubitemid 35223479)
40. Roszkowski, A. P., W. Rooks, A. Tomolonis, L. Miller, and A. B. Pelczarska. 1973. Pharmacological properties of naproxen. Scand. J. Rheumatol. Suppl. 2 (Suppl 2): 12-19.
41. Bell, R. L., P. R. Young, D. Albert, C. Lanni, J. B. Summers, D. W. Brooks, P. Rubin, and G. W. Carter. 1992. The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor. Int. J. Immunopharmacol. 14: 505-510.
42. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1996. Regulation of experimental autoimmune encephalomyelitis by interleukin-12. Ann. N. Y. Acad. Sci. 795: 216-226. (Pubitemid 27029570)
43. Kroenke, M. A., T. J. Carlson, A. V. Andjelkovic, and B. M. Segal. 2008. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205: 1535-1541. (Pubitemid 351962016)
44. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748. (Pubitemid 36227625)
45. Friese, M. A., X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger. 2006. The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952. (Pubitemid 44289061)
46. Chen, Y., C. L. Langrish, B. McKenzie, B. Joyce-Shaikh, J. S. Stumhofer, T. McClanahan, W. Blumenschein, T. Churakovsa, J. Low, L. Presta, et al. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116: 1317-1326.
47. Clemens, J. A., D. T. Stephenson, E. B. Smalstig, E. F. Roberts, E. M. Johnstone, J. D. Sharp, S. P. Little, and R. M. Kramer. 1996. Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Stroke 27: 527-535. (Pubitemid 26081453)
48. Stephenson, D., K. Rash, B. Smalstig, E. Roberts, E. Johnstone, J. Sharp, J. Panetta, S. Little, R. Kramer, and J. Clemens. 1999. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 27: 110-128. (Pubitemid 29365748)
49. Goverman, J. 2009. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9: 393-407.
50. Lafaille, J. J., K. Nagashima, M. Katsuki, and S. Tonegawa. 1994. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient antimyelin basic protein T cell receptor transgenic mice. Cell 78: 399-408. (Pubitemid 24250805)
51. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182: 75-85.
52. Tuohy, V. K., M. Yu, L. Yin, J. A. Kawczak, J. M. Johnson, P. M. Mathisen, B. Weinstock-Guttman, and R. P. Kinkel. 1998. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164: 93-100. (Pubitemid 28438399)
53. Rocha, P. N., T. J. Plumb, and T. M. Coffman. 2003. Eicosanoids: Lipid mediators of inflammation in transplantation. Springer Semin. Immunopathol. 25: 215-227.
54. James, M. J., P. S. Penglis, G. E. Caughey, M. Demasi, and L. G. Cleland. 2001. Eicosanoid production by human monocytes: Does COX-2 contribute to a selflimiting inflammatory response? Inflamm. Res. 50: 249-253. (Pubitemid 32453010)
55. Ousman, S. S., and S. David. 2001. MIP-1alpha, MCP-1, GM-CSF, and TNFalpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J. Neurosci. 21: 4649-4656. (Pubitemid 32565623)
56. Tager, A. M., S. K. Bromley, B. D. Medoff, S. A. Islam, S. D. Bercury, E. B. Friedrich, A. D. Carafone, R. E. Gerszten, and A. D. Luster. 2003. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4: 982-990. (Pubitemid 37265919)
57. Goodarzi, K., M. Goodarzi, A. M. Tager, A. D. Luster, and U. H. Von Andrian. 2003. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol. 4: 965-973. (Pubitemid 37265917)
58. Ott, V. L., J. C. Cambier, J. Kappler, P. Marrack, and B. J. Swanson. 2003. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol. 4: 974-981. (Pubitemid 37265918)
59. Ousman, S. S., and S. David. 2000. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 30: 92-104. (Pubitemid 30172156)
60. Kihara, Y., K. Yanagida, K. Masago, Y. Kita, D. Hishikawa, H. Shindou, S. Ishii, and T. Shimizu. 2008. Platelet-activating factor production in the spinal cord of experimental allergic encephalomyelitis mice via the group IVA cytosolic phospholipase A2-lyso-PAFAT axis. J. Immunol. 181: 5008-5014.
61. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in Tcell immunity. Curr. Opin. Immunol. 19: 309-314. (Pubitemid 46687017)
62. Schreiner, B., S. L. Bailey, T. Shin, L. Chen, and S. D. Miller. 2008. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur. J. Immunol. 38: 2706-2717.
63. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029.
64. Steinman, L. 2007. A brief history of T(H)17, the first major revision in the T(H) 1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139-145.